Dridi, Haikel http://orcid.org/0000-0001-9533-7367
Liu, Yang http://orcid.org/0000-0002-8343-4431
Reiken, Steven http://orcid.org/0000-0002-5807-3574
Liu, Xiaoping
Argyrousi, Elentina K. http://orcid.org/0000-0003-3716-807X
Yuan, Qi
Miotto, Marco C. http://orcid.org/0000-0001-8851-4863
Sittenfeld, Leah http://orcid.org/0000-0001-8349-0663
Meddar, Andrei http://orcid.org/0000-0002-2708-6153
Soni, Rajesh Kumar
Arancio, Ottavio http://orcid.org/0000-0001-6335-164X
Lacampagne, Alain
Marks, Andrew R. http://orcid.org/0000-0002-4316-5775
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL145473, R01HL142903, R01HL140934)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK118240)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01AR070194)
Article History
Received: 20 April 2022
Accepted: 12 June 2023
First Online: 10 July 2023
Competing interests
: Columbia University and A.R.M. own stock in ARMGO, a company developing compounds targeting RyR and have patents on Rycals. The remaining authors declare no competing interests.